[306 Pages Report] The HIV diagnostics market is anticipated to record a steady CAGR of 7.9% during the period 2022 to 2032.
During the forecast period, the HIV diagnostics market is predicted to rise from US$ 3.0 Billion in 2022 to US$ 6.4 Billion in 2032.
A favorable regulatory environment and substantial investment in Research and Development activities by market participants for the development of improved quality HIV testing kits for home use are likely to propel the HIV diagnostics market growth.
The demand for HIV diagnostics is forecasted to grow due to factors such as the rising global prevalence of HIV/AIDS, as well as the rising number of blood transfusions and blood donations.
| Attributes | Details |
|---|---|
| HIV Diagnostics Market CAGR (2022 to 2032) | 7.9% |
| HIV Diagnostics Market Value (2022) | US$ 3.0 Billion |
| HIV Diagnostics Market Value (2032) | US$ 6.4 Billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The COVID-19 outbreak had a negative impact on the HIV diagnostics market share. To combat community transmission of the COVID-19 virus, many parts of the world implemented preventive lockdowns. As a result, the sales of HIV diagnostic procedures and patient visits in healthcare institutions have decreased significantly, severely impacting the HIV diagnostics market growth.
A disruption in ART supply and preventive measures, according to a modeling exercise conducted by the WHO and UNAIDS for Sub-Saharan Africa, might increase HIV-related mortality and new infections across the region. Due to this factor, the demand for HIV diagnostics increased.
As a precaution, countries were asked to establish a strategy for maintaining HIV prevention and treatment services throughout the COVID-19 pandemic. Unless immediate action was taken to ensure a continuous supply of pharmaceuticals and access to preventative treatments, the nations' gains would be lost.
The demand for HIV diagnostics grew significantly in 2021 as the number of COVID-19 patients decreased. The sales of HIV diagnostic procedures in settings with lower risk of infection have increased as a result of healthcare facilities establishing standard operating practices and a lower death rate linked to COVID-19.
As a result of the shrinking COVID-19 patient population, the sales of HIV diagnostic procedures and overall market share are likely to increase significantly in the near future.
The demand for HIV diagnostics is growing as it detects the presence of the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome. HIV diagnostics is accomplished by performing tests on serum, saliva, or urine samples.
The sales of HIV diagnostic procedures are anticipated to grow as these techniques aid in detecting antibodies, antigens, and RNA. Furthermore, the demand for HIV diagnostics is growing as people become more aware of HIV, the test's secrecy, and appropriate counselling. Due to these factors, the HIV diagnostics market is projected to grow rapidly.
The demand for HIV diagnostics tests is anticipated to grow as they are critical in the accurate diagnosis and management of a person's health. The HIV diagnostics market share is projected to rise as more HIV diagnostics tests become available around the world.
However, the high costs of Nucleic Acid Testing (NAT) and the lack of NAT mandates in underdeveloped nations are limiting the growth of the HIV diagnostics market expansion.
The demand for HIV diagnostics is projected to rise as they provide simple quick assays with visual testing, as well as easy-to-handle home sample collecting approaches that may be utilized by health care personnel and customers at home. These factors are responsible for boosting the sales of HIV diagnostic procedures and have paved the way for the HIV diagnostics market to grow.
The sales of HIV diagnostic procedures are anticipated to grow due to the benefits provided by point-of-care tools and kits and increased government initiatives.
Rapid HIV tests are often known as point-of-care (PoC) HIV tests. HIV diagnosis often entails pre-test counselling, HIV testing, and post-test counselling, with patients expected to return for test results at a later date.
While the patient is still in the lab for PoC HIV diagnosis, counselling and screening are done simultaneously. If necessary, confirmation tests are performed. Individuals are not obliged to return for their results because pre-test and post-test counselling are done at the same time in PoC testing, making it a very convenient alternative.
As a result of this, the demand for HIV diagnostics is projected to rise at a significant pace during the forecast period.
The sales of HIV diagnostics procedures are projected to rise as rapid HIV testing yields results in about 30 minutes, removing the stress of waiting for results. Undiagnosed HIV cases and those who have not returned for follow-up testing are the major reasons for rapid HIV testing.
The demand for HIV diagnostics improved PoC kits and equipment is increasing as a consequence of its multiple benefits, which is projected to aid in the growth of the HIV diagnostics market size in the coming years.
Principal Consultant
HIV Diagnostics Market:
| Attributes | HIV Diagnostics Market |
|---|---|
| CAGR (2022 to 2032) | 7.9% |
| Market Value (2026) | US$ 4.07 Billion |
| Growth Factor | The rising global prevalence of HIV/AIDS, as well as the rising number of blood transfusions and blood donations. |
| Opportunity | Due to multiple advantages, the demand for technologically advanced PoC kits and instruments is on the rise |
| Key Trends | Key players' substantial investment in Research and Development efforts for the development of improved quality HIV testing kits for home use. |
STD Diagnostics Market:
| Attributes | STD Diagnostics Market |
|---|---|
| CAGR (2022 to 2032) | 4.8% |
| Market Value (2026) | US$ 121.09 Billion |
| Growth Factor | Increased public awareness and patient education to drive market growth. |
| Opportunity | Countries around the world are focused on implementing nationwide screening tests to boost STD diagnosis coverage. |
| Key Trends | The change from conventional methods to molecular diagnostics for the detection of STDs. |
Point of Care Testing Market:
| Attributes | Point of Care Testing Market |
|---|---|
| CAGR (2022 to 2032) | 7.4% |
| Market Value (2026) | US$ 44.51 Billion |
| Growth Factor | POCT services have grown in popularity as the prevalence of chronic diseases and acute infections has increased around the world. |
| Opportunity | The demand for point-of-care tests for rapid diagnosis is growing due to their convenience of use, cost-effectiveness, and small product size. |
| Key Trends | POCT compliance, safety, and usability have become increasingly important as the scope of use and penetration in developing economies has grown. |
According to the Centers for Disease Control and Prevention (CDC), people aged 13 to 64 should be tested for HIV at least once as part of a routine health check. As a result of this, the HIV diagnostics
The demand for HIV diagnostics is rising as HIV infection remains a major public health concern around the world. As a result, the sales of HIV diagnostic procedures are also predicted to rise as HIV diagnosis has become increasingly vital in order to prevent the disease from spreading further.
The global HIV diagnostics market is booming due to rising demand for rapid testing and point-of-care (PoC) HIV tests around the world. In addition, people's disposable income is increasing, which is encouraging the HIV diagnostics market growth.
Expanding government and private sector awareness campaigns regarding HIV diagnostics and testing processes, as well as the growing presence of various industry players in this region, are projected to have a beneficial impact on the demand for HIV diagnostics. Furthermore, the increasing use of point-of-care testing in numerous nations is likely to propel African countries to use HIV diagnostic tests.
The consumable sector accounted for the largest market share in the global HIV diagnosis market. Consumption of consumables such as assays, reagents, and kits is on the rise, which is propelling the HIV diagnostics market forward.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The hospital sector is expected to lead the HIV diagnostics market, by end-use, and grow at a CAGR of 7.2% over the projected period. Continuous technical developments in laboratory devices are likely to support segment expansion by improving testing outcomes.
With a CAGR of 7.0%, the body tests are predicted to account for the biggest proportion of the market by test type. This substantial percentage can be ascribed to advances in HIV diagnosis technology, increased HIV awareness, and increased blood donations.
| Regions | CAGR (2022 to 2032) |
|---|---|
| USA Market | 7.4% |
| UK Market | 6.7% |
| China Market | 7.2% |
| Japan Market | 6.2% |
| South Korea Market | 5.5% |
Due to rising product approval in the area, North America is predicted to dominate the global HIV diagnostics market. The US Food and Treatment Administration (FDA) granted Vela Diagnostics de novo approval for its Sentosa SQ HIV-1 Genotyping Assay, which was created to detect HIV-1 genomic drug resistance mutations (DRMs).
Abbott Laboratories gained WHO Prequalification approval (WHO PQ) for m-PIMA HIV-1/2 VL, the first point-of-care viral load diagnostic test, in May 2019. The portable molecular point-of-care test is intended for use in resource-constrained environments. The product's prequalification status makes it eligible for purchase by United Nations organizations.
According to the European Centre for Disease Prevention and Control (ECDC) study from 2017, over 51 percent of all HIV cases in Europe were detected late in 2015, and around 28 percent had progressed HIV infection. Furthermore, in nine European nations, including Austria, Estonia, Greece, Italy, Latvia, Lithuania, Romania, Slovenia, and Sweden, the rate of late diagnoses was greater than 50%.
In 2021, the African HIV diagnostics market accounted for approximately 38% of the global market, and it is expected to continue to rise rapidly over the analyzed period. High rates of HIV infections in African countries due to rising rates of teenage pregnancy, and a lack of quality sex education are some of the primary drivers of regional HIV diagnostics market expansion.
The HIV diagnostics market is likely to be driven by rising knowledge of available HIV aids treatment options and cost-effective HIV medication therapy. However, the quick replacement of HIV-AIDS treatments and therapies by new drugs and therapies, as well as patient protection losses, are limiting the worldwide HIV diagnostics market's growth.
The growth of the HIV diagnostics market in Asia is likely to be led by developing countries such as India and China, which have growing demographics and economies. Furthermore, the global HIV diagnostics market is likely to benefit from increased knowledge about HIV-AIDS treatment and technological advancements in HIV-AIDS testing.
There are a few major competitors in the HIV diagnostics market. To stay competitive in the HIV diagnostics market, these companies are using a variety of growth tactics such as collaboration, acquisition & merger, partnership, and new launches.
Recent Developments in the HIV Diagnostics Market
The HIV diagnostics market is projected to register a CAGR of 7.9% during the period 2022 to 2032.
North America is predicted to dominate the global HIV diagnostics market.
The hospitals sector is expected to lead the HIV diagnostics market by end use.
The HIV diagnostics market is anticipated to grow from US$ 3.0 Billion in 2022 to US$ 6.4 Billion by 2032.
Asia Pacific (APAC) region has the highest growth potential in the HIV diagnostics market.
1. Executive Summary | HIV Diagnostics Market 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on HIV Diagnostics 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Million) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Market, by Key Countries 4.2. Market Opportunity Assessment (US$ Million) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in Optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Patch Management Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032 6.1. Historical Market Analysis, 2015 to 2021 6.2. Current and Future Market Projections, 2022 to 2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2015 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Product, 2015 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2022 to 2032 8.3.1. Consumables 8.3.2. Instruments 8.3.3. Software & Services 8.4. Market Attractiveness Analysis By Product 9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Test Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Test Type, 2015 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032 9.3.1. Antibody Tests 9.3.2. Viral Load Tests 9.3.3. CD4 Tests 9.3.4. Others 9.4. Market Attractiveness Analysis By Test Type 10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By End User, 2015 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032 10.3.1. Diagnostic Laboratories 10.3.2. Hospitals 10.3.3. Others 10.4. Market Attractiveness Analysis By End User 11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2015 to 2021 11.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2022 to 2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Asia Pacific 11.3.5. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 12.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 12.4.1. By Country 12.4.1.1. United States of America 12.4.1.2. Canada 12.4.1.3. Rest of North America 12.4.2. By Product 12.4.3. By End User 12.4.4. By Test Type 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Product 12.5.3. By End User 12.5.4. By Test Type 13. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 13.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 13.4.1. By Country 13.4.1.1. Brazil 13.4.1.2. Mexico 13.4.1.3. Rest of Latin America 13.4.2. By Product 13.4.3. By End User 13.4.4. By Test Type 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Product 13.5.3. By End User 13.5.4. By Test Type 14. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 14.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 14.4.1. By Country 14.4.1.1. Germany 14.4.1.2. France 14.4.1.3. United Kingdom 14.4.1.4. Italy 14.4.1.5. Benelux 14.4.1.6. Nordic Countries 14.4.1.7. Rest of Europe 14.4.2. By Product 14.4.3. By End User 14.4.4. By Test Type 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Product 14.5.3. By End User 14.5.4. By Test Type 15. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 15.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 15.4.1. By Country 15.4.1.1. China 15.4.1.2. Japan 15.4.1.3. South Korea 15.4.1.4. Rest of Asia Pacific 15.4.2. By Product 15.4.3. By End User 15.4.4. By Test Type 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Product 15.5.3. By End User 15.5.4. By Test Type 16. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2015 to 2021 16.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2022 to 2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Turkey 16.4.1.4. Rest of Middle East and Africa 16.4.2. By Product 16.4.3. By End User 16.4.4. By Test Type 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Product 16.5.3. By End User 16.5.4. By Test Type 17. Key Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. US Market Analysis 17.2.1. Value Proportion Analysis by Market Taxonomy 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.2.2.1. By Product 17.2.2.2. By End User 17.2.2.3. By Test Type 17.3. Canada Market Analysis 17.3.1. Value Proportion Analysis by Market Taxonomy 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.3.2.1. By Product 17.3.2.2. By End User 17.3.2.3. By Test Type 17.4. Mexico Market Analysis 17.4.1. Value Proportion Analysis by Market Taxonomy 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.4.2.1. By Product 17.4.2.2. By End User 17.4.2.3. By Test Type 17.5. Brazil Market Analysis 17.5.1. Value Proportion Analysis by Market Taxonomy 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.5.2.1. By Product 17.5.2.2. By End User 17.5.2.3. By Test Type 17.6. Germany Market Analysis 17.6.1. Value Proportion Analysis by Market Taxonomy 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.6.2.1. By Product 17.6.2.2. By End User 17.6.2.3. By Test Type 17.7. France Market Analysis 17.7.1. Value Proportion Analysis by Market Taxonomy 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.7.2.1. By Product 17.7.2.2. By End User 17.7.2.3. By Test Type 17.8. Italy Market Analysis 17.8.1. Value Proportion Analysis by Market Taxonomy 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.8.2.1. By Product 17.8.2.2. By End User 17.8.2.3. By Test Type 17.9. BENELUX Market Analysis 17.9.1. Value Proportion Analysis by Market Taxonomy 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.9.2.1. By Product 17.9.2.2. By End User 17.9.2.3. By Test Type 17.10. UK Market Analysis 17.10.1. Value Proportion Analysis by Market Taxonomy 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.10.2.1. By Product 17.10.2.2. By End User 17.10.2.3. By Test Type 17.11. Nordic Countries Market Analysis 17.11.1. Value Proportion Analysis by Market Taxonomy 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.11.2.1. By Product 17.11.2.2. By End User 17.11.2.3. By Test Type 17.12. China Market Analysis 17.12.1. Value Proportion Analysis by Market Taxonomy 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.12.2.1. By Product 17.12.2.2. By End User 17.12.2.3. By Test Type 17.13. Japan Market Analysis 17.13.1. Value Proportion Analysis by Market Taxonomy 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.13.2.1. By Product 17.13.2.2. By End User 17.13.2.3. By Test Type 17.14. South Korea Market Analysis 17.14.1. Value Proportion Analysis by Market Taxonomy 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.14.2.1. By Product 17.14.2.2. By End User 17.14.2.3. By Test Type 17.15. GCC Countries Market Analysis 17.15.1. Value Proportion Analysis by Market Taxonomy 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.15.2.1. By Product 17.15.2.2. By End User 17.15.2.3. By Test Type 17.16. South Africa Market Analysis 17.16.1. Value Proportion Analysis by Market Taxonomy 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.16.2.1. By Product 17.16.2.2. By End User 17.16.2.3. By Test Type 17.17. Turkey Market Analysis 17.17.1. Value Proportion Analysis by Market Taxonomy 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015 to 2032 17.17.2.1. By Product 17.17.2.2. By End User 17.17.2.3. By Test Type 17.17.3. Competition Landscape and Player Concentration in the Country 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 18.4.1. By Regional Footprint of Players 18.4.2. Product Footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. Siemens Healthineers 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Sales Footprint 19.3.1.4. Strategy Overview 19.3.2. F. Hoffmann-La Roche Ltd 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Sales Footprint 19.3.2.4. Strategy Overview 19.3.3. Abbott Laboratories 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Sales Footprint 19.3.3.4. Strategy Overview 19.3.4. Danaher Corporation 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Sales Footprint 19.3.4.4. Strategy Overview 19.3.5. Thermo-Fisher Scientific Inc 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Sales Footprint 19.3.5.4. Strategy Overview 19.3.6. Merck KGaA 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Sales Footprint 19.3.6.4. Strategy Overview 19.3.7. Becton, Dickinson & Company 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Sales Footprint 19.3.7.4. Strategy Overview 19.3.8. Hologic Inc 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Sales Footprint 19.3.8.4. Strategy Overview 19.3.9. Bio-Rad Laboratories 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Sales Footprint 19.3.9.4. Strategy Overview 19.3.10. Alere Inc 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Sales Footprint 19.3.10.4. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
HIV Diagnostics Market
